Destiny Pharma (LSE:DEST) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Destiny Pharma Debt-to-Equity?

Destiny Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.00 Mil. Destiny Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.00 Mil. Destiny Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was £9.19 Mil. Destiny Pharma's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Destiny Pharma's Debt-to-Equity or its related term are showing as below:

LSE:DEST's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.145
* Ranked among companies with meaningful Debt-to-Equity only.

Destiny Pharma Debt-to-Equity Historical Data

The historical data trend for Destiny Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Destiny Pharma Debt-to-Equity Chart

Destiny Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

Destiny Pharma Semi-Annual Data
	Dec14	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Destiny Pharma's Debt-to-Equity

For the Biotechnology subindustry, Destiny Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Destiny Pharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Destiny Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Destiny Pharma's Debt-to-Equity falls into.

Destiny Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Destiny Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	9.189
	=	0.00

Destiny Pharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	9.189
	=	0.00

Destiny Pharma (LSE:DEST) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Destiny Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Destiny Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Destiny Pharma (LSE:DEST) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Destiny Pharma PLC (LSE:DEST) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

D89:Germany

Address

Unit 36, Sussex Innovation Centre, Science Park Square, Falmer, Brighton, GBR, BN1 9SB

Website

https://www.destinypharma.com

Destiny Pharma PLC is a clinical-stage biotechnology company which is focused on the development of medicines for the treatment of infectious disease. It is developing drugs for the prevention and treatment of infections caused by Antibiotic-Resistant (AR) bacteria. It is involved in developing XF-73 Dermal for the treatment of skin infections of antibiotic-resistant bacteria, XF-73 Nasal for prevention of post-surgical staphylococcal infection, XF Throat for prevention of staphylococcal hospital/ventilator-associated pneumonia infection.

Destiny Pharma (LSE:DEST) Headlines

No Headlines